According to a recent LinkedIn post from AcuityMD, the company is highlighting internal data on the accelerating shift of endoscopic colorectal procedures from hospitals to ambulatory surgery centers, or ASCs, in the U.S. The post indicates that ASCs now handle the majority of such procedures, with procedure volume up roughly 50% since 2018 to an estimated 9 million in 2024, and shows notable regional variation in ASC market share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests that this site-of-care migration could materially affect how MedTech firms prioritize sales resources, facility relationships, and reimbursement strategies. For AcuityMD, which provides data-driven commercial tools, emphasizing the ability to detect such trends early may strengthen its value proposition to MedTech customers and could support future revenue growth if adoption of its analytics platform increases alongside this structural shift.
The post also underscores that relying on hospital-centric volume may no longer reflect the current market in colorectal care and potentially other specialties. If investors interpret this as evidence that more procedure categories are moving into ASCs, demand for granular, location-specific market intelligence may grow, positioning AcuityMD to benefit as MedTech companies adapt their commercial strategies to the evolving care landscape.